

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

PAR PHARMACEUTICAL, INC.,

Petitioner,

v.

NOVARTIS AG,

Patent Owner.

Case IPR2016-00084

Patent No. 5,665,772

**EXPERT DECLARATION OF
DR. HOWARD A. BURRIS, III**

Contents

I.	Academic And Professional Qualifications.....	1
II.	Applicable Legal Principles.....	5
III.	Summary Of Opinions.....	7
IV.	Renal Cell Carcinoma.....	13
	A. Overview	13
	B. In October 1992, There Was A Long-Felt Unmet Need For Safe And Effective Pharmaceutical Therapies For Advanced RCC.....	14
	C. Others Tried And Failed To Develop New Therapies For Advanced RCC.....	17
	D. Everolimus Satisfied A Long-Felt Unmet Need For A Safe And Effective Therapy For Advanced RCC	21
V.	Advanced Breast Cancer	27
	A. Overview	27
	B. In October 1992, There Was A Long-Felt Unmet Need For Safe And Effective Pharmaceutical Therapies For Advanced Breast Cancer	30
	C. Others Tried And Failed To Develop New Therapies For Advanced Breast Cancer	34
	D. Everolimus Satisfied A Long-Felt Unmet Need For A Safe And Effective Therapy For Advanced Breast Cancer	35
VI.	A POSA In October 1992 Would Not Have Had A Reasonable Expectation That Everolimus Would Have Its Antitumor Activity	39
	A. Overview	39
	B. The <i>In Vivo</i> Antitumor Activity Of Rapamycin Was Unpredictable In October 1992	43

C.	A POSA In October 1992 Would Not Have Reasonably Predicted What Effect A Structural Difference Would Have On Antitumor Activity.....	49
D.	A POSA In October 1992 Would Not Have Reasonably Expected Everolimus To Have Its Observed Antitumor Activity.....	51
E.	A POSA In October 1992 Would Not Have Reasonably Expected The Antitumor Activity Of Everolimus Simply Because It Was A Rapamycin Analog.....	58
F.	The Absence Of Clinical Testing Of Rapamycin Prior To October 1992 Provides Additional Evidence That The Antitumor Activity Of Everolimus Would Have Been Unexpected.....	62
VII.	Everolimus Has Demonstrated Unexpected Properties.....	64
A.	Overview.....	64
B.	The Combination Of FDA Approvals Of Everolimus Would Have Been Unexpected In October 1992.....	65
C.	Rapamycin Has Not Demonstrated The Same Clinical Efficacy As Everolimus.....	67
D.	The Rapamycin Analog Temsirolimus Has Not Demonstrated The Same Clinical Efficacy As Everolimus.....	88
VIII.	Physicians Prescribe Afinitor [®] (Everolimus) Because Of The Clinical Benefits Of Everolimus.....	90
IX.	Everolimus Has Received Industry Praise For Its Use In The Treatment Of Advanced RCC and Breast Cancer.....	95

I, Dr. Howard A. Burris, III, declare as follows:

I. Academic And Professional Qualifications

1. I am a board certified Oncologist at the Sarah Cannon Research Institute in Nashville, Tennessee. I am currently the President of Clinical Operations, the Executive Director of Drug Development, and the Chief Medical Officer at Sarah Cannon Research Institute. I am also an Associate at Tennessee Oncology, PLLC in Nashville. I began working in both the renal cell carcinoma field and the breast cancer field in 1988. I have been involved in 27 everolimus clinical trials, including 9 related to renal cell carcinoma and 9 related to breast cancer. My curriculum vitae, which lists my professional experience and academic qualifications, is attached hereto as Exhibit 2096.

2. I obtained my B.S. in chemistry in 1981 at the West Point United States Military Academy. I obtained a Doctor of Medicine degree at the University of South Alabama, College of Medicine in 1985. Between 1985 and 1991, I completed my Internship, Residency in Internal Medicine, and Fellowship in Hematology/Medical Oncology at Brooke Army Medical Center at Fort Sam Houston in San Antonio, Texas.

3. From 1990 to 1991, I was a Clinical Instructor in the Department of Medicine/Oncology at The University of Texas Health Science Center in San Antonio, Texas. From 1991 to 1997, I was a staff member in

Hematology/Oncology Service at both the Cancer Therapy and Research Center of South Texas and the Brooke Army Medical Center. Between 1991 and 1996, I was an Assistant Professor in the Department of Medicine/Oncology at The University of Texas Health Science Center, and from 1996 to 1997, I was an Associate Professor there. From 1992 to 1995, I was the Associate Director, and then the Director, of Clinical Research in the Institute for Drug Development at the Cancer Therapy and Research Center of South Texas. And, from 1990 through 1997, I was the Director of the Drug Development Program at the Brooke Army Medical Center.

4. I am a member of the following Professional Associations: American Society of Hematology; Southwest Oncology Group; Southern Association for Oncology (Affiliation of Southern Medical Association); and the International Association for the Study of Lung Cancer. I am also a Board Member of Gilda's Club.

5. I have been involved with the American Society of Clinical Oncology (ASCO). I am currently on the following ASCO committees: Cancer Education Committee, Track Leader; Cancer Research Committee; Clinical Trial Participation Award (CTPA) Review Committee; and the Community Research Forum Council, Chair. In the past, I have been on the following ASCO committees: Board of Directors; Nominating Committee, Chair; Clinical Practice

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.